DRG International, Inc., established in 1970, is the leading supplier and manufacturer of ELISA medical diagnostic test kits for clinical and research applications worldwide. DRG also supplies clinical laboratory equipment to complete the diagnostic reagent line.DRGŪ is well known and respected in the diagnostic industry for its reliable performance, good service, and high-quality products with long shelf life and reliable after sale service. Our major product line covers the full range of hormones used in gynecology and obstetrics, as well as endocrinology, diabetes, infectious diseases, saliva kits and tumor markers for diagnostic and R&D purposes.In addition to a wide range of ELISA kits for endocrinology, diabetes, infectious diseases and tumor markers for diagnostic/R&D purposes, DRGŪ is pleased to introduce new Prenatal Supervision kits: PLGF ELISA (new marker for Preeclampsia), as well as the the new Active RENIN (hypertension) and anti-Amyloid-Beta Ab (Alzheimers disease) ELISA kit and the newest, improved version of DRG Tumor marker panel.DRGŪ also offers Iron Metabolism products particularly the Hepcidin Prohormone and the Hepcidin (c-terminal) ELISA kit (U.S. Patents 7,320,894 and 7,411,048)To learn more about the DRGŪ Group and our complete product line, please visit our corporate website at www.drg-international.com .
|DRGŪ Hepcidin ELISA (EIA-4705)|
Principle of the test
The DRG Hepcidin ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA), based on
the principle of competitive binding.
The microtiter wells are coated with a monoclonal antibody directed towards the antigenic site of the
bioactive Hepcidin 25 molecule.
Endogenous Hepcidin of a patient sample competes with the added Hepcidin-biotin conjugate for binding
to the coated antibody. After incubation the unbound conjugate is washed off.
An incubation with a streptavidin-peroxidase enzyme complex and a second wash step follows.
The addition of substrate solution results in a colour development which is stopped after a short
The intensity of colour developed is reverse proportional to the concentration of Hepcidin in the patient